Smoking cessation may reduce risk of rheumatoid arthritis

"Ours is the first study to show that a behavior change can reduce risk for seropositive RA. Risk isn't just about genes and bad luck -- there's a modifiable environmental component to the onset of this disease and a chance for some people to reduce their risk or even prevent RA," said corresponding author Jeffrey Sparks, MD, MMSc, of the Division of Rheumatology, Immunology and Allergy at the Brigham.

To conduct their study, Sparks and colleagues used data from the original Nurses' Health Study, established in 1976, and Nurses' Health Study II, a second cohort established in 1989. Both groups include registered nurses from across the U.S. who filled out health surveys every two years with questions that included information about smoking and health status. Among more than 230,000 participants in this analysis, the researchers identified 1,528 who developed RA. The research team was especially interested in the 969 "seropositive" as opposed to "seronegative" cases. Patients with seropositive RA have auto-antibodies related to RA, and generally have more severe disease manifestations, including joint deformities and disability.

For seropositive RA, risk began to go down about five years after women quit smoking and continued to decrease the longer they stayed non-smokers. Participants who quit for good reduced their risk of seropositive RA by 37 percent after 30 years. The team did not find any association between seronegative RA and smoking, adding further evidence to the theory that seronegative and seropositive RA may be two distinct diseases with distinct risk factors.

"One of the lessons here is that it takes sustained smoking cessation to reap the full benefit," said Sparks. "Whereas for other diseases, such as cardiovascular disease, quitting smoking can provide a more immediate effect, here we're seeing benefits decades later for those who quit smoking permanently."

While the biological mechanisms that link smoking and the development of RA are unclear, Sparks and others think that smoking may affect a preclinical disease process that leads to the formation of RA-related auto-antibodies and increases inflammation. In addition to further studying the biology of RA, Sparks and colleagues want to extend their investigations to include men and interventional trials among active smokers to see if it is possible to prospectively prevent the formation of RA-related auto-antibodies and the progression of the disease among those at increased risk.

This work was supported by the National Institutes of Health (grant numbers K23 AR069688, L30 AR066953, R01 AR049880, K24 AR052403, UM1 CA186107, UM1 CA176726, P30 AR070253, and P30 AR072577).